RORγt agonist 3 (extracted from patent WO2021136326A1, compound 23) is a novel agonist of RORγt with anticancer and immunomodulatory effects. It promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells.
RORgammat agonist 3 (Compound 23 in patent WO2021136326A1) is a potent agonist of the retinoic acid receptor-related orphan receptor gamma t (RORgammat), a key transcription factor driving Th17 cell differentiation. It promotes pro-inflammatory cytokine production and enhances lymphocyte cytotoxicity, making it of interest for cancer immunotherapy and immunomodulation research. Targets: RORgammat (RORC, retinoic acid receptor-related orphan receptor gamma t). RORgammat agonist 3 binds to the ligand-binding domain (LBD) of RORgammat, inducing a conformational change that recruits co-activators and activates transcription of Th17-specific genes, including IL-17A, IL-17F, IL-22, and GM-CSF. This shifts the immune balance toward a pro-inflammatory Th17 phenotype. In vitro, RORgammat agonist 3 (0.1-10 uM) induces Th17 cell differentiation from naive CD4+ T cells in the presence of TGF-beta and IL-6, increasing production of IL-17A and IL-22. It also enhances the cytotoxicity of CD8+ T lymphocytes (CTLs) against tumor cells in co-culture assays. No in vivo efficacy data have been published specifically for this compound in animal models. Based on its mechanism, RORgammat agonist 3 is expected to enhance anti-tumor immunity in syngeneic mouse tumor models (e.g., B16 melanoma, CT26 colon cancer) by promoting Th17 responses and CTL activation. Potential application in adoptive T cell therapy. For cell-free binding assays: recombinant RORgammat-LBD protein is incubated with varying concentrations of RORgammat agonist 3 (0-100 uM) and a fluorescence-labeled tracer in assay buffer. TR-FRET (time-resolved fluorescence resonance energy transfer) is used to measure binding displacement, with IC50/EC50 derived from dose-response curves. For cell-based Th17 differentiation assays: naive CD4+ T cells from mouse spleen or human PBMCs are purified, activated with anti-CD3/CD28 in the presence of RORgammat agonist 3 (0.1-10 uM) and polarizing cytokines (TGF-beta, IL-6, anti-IFN-gamma, anti-IL-4). After 4-5 days, supernatant IL-17A and IL-22 are measured by ELISA, and intracellular cytokine staining is performed for flow cytometry. For animal studies: potential in vivo protocol involves daily oral administration of RORgammat agonist 3 (5-20 mg/kg) in syngeneic tumor-bearing mice for 14-21 days. Tumor volume is monitored. Splenocytes are analyzed for Th17 frequency by flow cytometry, and tumor-infiltrating lymphocytes (TILs) are assessed for CTL activity by IFN-gamma ELISPOT. No PK data are available for RORgammat agonist 3. For small molecule RORgammat agonists (MW ~567.74, predicted ClogP ~5.6), expected PK in mice: good oral bioavailability (~40-60%), moderate clearance, terminal half-life 4-8 h, and moderate volume of distribution. Brain penetration is likely due to high lipophilicity. No toxicity data have been reported for RORgammat agonist 3. Based on its agonism of RORgammat, systemic administration may cause autoimmunity, inflammatory bowel disease, and psoriasis-like skin inflammation due to excessive Th17 activation. Potential for cytokine release syndrome. RORgammat agonist 3 is a research compound not yet approved for clinical use. It is a tool for studying RORgammat biology in cancer immunotherapy and Th17-mediated autoimmune diseases. It could serve as a lead compound for developing adjuvants for cancer vaccines or for enhancing CAR-T cell efficacy.

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.